AI Article Synopsis
- A double-blind, placebo-controlled crossover study with ten healthy young males evaluated the effects of nocloprost on gastric injuries caused by aspirin.
- Nocloprost significantly reduced gastric microbleeding and nearly eliminated mucosal injury from aspirin without affecting gastric acid or pepsin secretion.
- The treatment also increased salivary and plasma levels of epidermal growth factor (EGF), suggesting its protective effects against gastric injury may involve EGF release.
Article Abstract
Ten healthy young male subjects took part in a double-blind, placebo-controlled crossover study to assess the effects of nocloprost on gastric microbleeding and endoscopic mucosal injury induced by the administration of aspirin (2.5 g). In addition, basal and pentagastrin-induced gastric acid and pepsin secretion and salivary and plasma contents of epidermal growth factor (EGF) were measured after placebo plus aspirin or nocloprost plus aspirin treatment in these subjects. Nocloprost (100 micrograms/dose) significantly reduced spontaneous gastric microbleeding and almost completely prevented gastric mucosal injury induced by aspirin. Nocloprost failed to affect basal and pentagastrin-stimulated gastric acid and pepsin secretion but increased significantly the salivary outputs and plasma concentrations of EGF. In conclusion, nocloprost is effective in preventing gastric injury by aspirin even at a non-antisecretory dose, and this protection may involve an excessive release of EGF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365529109025036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Strategy for NSAID administration to aspirin-intolerant asthmatics in combination with PGE2 analogue: a theoretical approach.
Med Biol Eng Comput
January 2012
Faculty of Natural Sciences and Mathematics, University of Maribor, Maribor, Slovenia.
Aspirin-induced asthma (AIA) is a severe inflammatory disease, which affects aspirin-intolerant patients after ingestion of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). In this article, a mathematical model describing arachidonic acid metabolism and its interaction with NSAIDs, is used to study the strategy for safe managing of NSAIDs to AIA patients. Three different AIA patient populations are taken into consideration.
View Article and Find Full Text PDFRole of expression of prostaglandin synthases 1 and 2 and leukotriene C4 synthase in aspirin-intolerant asthma: a theoretical study.
J Pharmacokinet Pharmacodyn
April 2011
Faculty of Natural Sciences and Mathematics, Faculty of Medicine, Faculty of Health Sciences, University of Maribor, Slomškov trg 15, 2000 Maribor, Slovenia.
Altered expressions of the key enzymes in arachidonic acid (AA) metabolism, prostaglandin synthase 1 and 2 and cysteinyl leukotriene C(4) synthase, are of importance in understanding aspirin-induced asthma. We propose a mathematical model of AA metabolism and its interaction with non-steroidal anti-inflammatory drugs (NSAIDs). Model simulations depict the impact of modified expressions of the above enzymes on the time dependent synthesis of cysteinyl leukotrienes and anti-inflammatory prostaglandins before and during NSAID exposure in different model states describing healthy humans as well as aspirin-tolerant and -intolerant asthmatics.
View Article and Find Full Text PDFEffects of nocloprost clathrate on absorption of acetylsalicylic acid.
Int J Clin Pharmacol Ther
January 1994
Department of Clinical Pharmacology, Medical Faculty, Ernst-Moritz-Arndt-University, Greifswald, Germany.
The cytoprotective prostaglandin E2 analog nocloprost clathrate (NOCLO) is tested as a prophylactic for gastrointestinal lesions of NSAID. The effects of 400 micrograms NOCLO versus respective placebos with and without equivalent amounts of beta-cyclodextrin on the pharmacokinetic behavior of acetylsalicylic acid (ASA), given 30 min after NOCLO, were studied in two single-blind, parallel-group trials. The trials were performed in 15 male healthy volunteers (age 21-25 years, body weight 62-94 kg, body height 172-187 cm) with known N-acetylation and debrisoquine type hydroxylation phenotype.
View Article and Find Full Text PDFPharmacokinetic interactions between nocloprost, acetylsalicylic acid and ethanol.
Int J Clin Pharmacol Ther Toxicol
November 1992
Department of Clinical Pharmacology, Medical Faculty, University of Greifswald, Germany.
Nocloprost, a unique prostaglandin E2 analog with local gastroprotective and ulcer-healing activity.
Eur J Pharmacol
April 1991
Institute of Physiology, Academy of Medicine, Kraków, Poland.
Article Synopsis
- Nocloprost, a prostaglandin E2 (PGE2) analog, was tested for its ability to protect against gastric lesions and promote ulcer healing in rats.
- It effectively prevented gastric damage from various stressors and was more effective when combined with stomach acid, lasting about 8 hours and outperforming another similar compound, dmPGE.
- Unlike dmPGE, nocloprost accelerated the healing of chronic gastric ulcers and enhanced mucosal growth, showing its strong local cytoprotective effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!